Tagged with P

Europe Advanced Therapy Medicinal Products (ATMPs) – encompassing gene therapies, somatic-cell therapies, and tissue-engineered products – have been regulated in the European Union under a dedicated framework since 2009. As of 2025, the European Medicines Agency (EMA) has authorised close to 20 ATMPs (below), most of them gene therapies for rare…

China This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Novartis’ USD 5.4bn expansion with Argo in cardiovascular siRNA, Hengrui’s USD 1.1bn out-licensing of its cardiac myosin inhibitor, Novatim’s USD 1.15bn ADC deal with Radiance, Convalife’s Hong Kong IPO filing, and Fosun’s TYK2/JAK1 rights buy. On the clinical side,…

Switzerland New Idorsia CEO Srishti Gupta is emphasising “financial discipline” as she looks to turn around the fortunes of one of Europe’s top biotechs.   Challenging Times Gupta, who spent almost two decades at consultancy firm McKinsey, inherits a company that managed to launch three drugs in its first seven years…

China The top 20 Chinese pharma companies ranked by 2023 sales, according to the Citelie Scrip Asia 100. CSPC, Fosun, and Shanghai Pharma top the chart, with a host of other less well-known firms now also generating over a billion dollars in annual sales.   Made with Visme Infographic Maker

Switzerland As Medinova marks 80 years since its founding in Zurich, General Manager Olga Lamua Olivar is charting the path forward for the boutique specialty pharma player. With a career spanning multiple countries and disciplines, she brings the breadth of experience needed to guide Medinova through its next transformation. Her strategy…

Switzerland Amid structural reforms and shifting expectations across the Swiss healthcare system, Marco Caruso’s return to Medtronic marks a renewed focus on patient impact, equitable access, and long-term value. Speaking from the intersection of leadership, policy, and innovation, Caruso offers sharp insights into how one of the world’s largest medtech companies…

Polepharma Fabien Riolet leads Polepharma, France’s leading pharmaceutical manufacturing network, driving industrial sovereignty and innovation across 460 member companies. Under his leadership, it has evolved into a strategic hub for manufacturing excellence, digital transformation, and sustainability, while positioning France for next-generation biopharma competitiveness. Our mission is clear: to preserve and strengthen…

France With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR 750 million investment in a new industrial site and a unique public health mandate, the state-owned player is not just…

Switzerland Fabien Stutz, Co-Founder and CEO of Pharmabotix, leads a new wave of pharma-tech entrepreneurs combining engineering expertise with cutting-edge automation. He has helped grow the Swiss-based company into a globally recognised firm, delivering bespoke systems to major clients across Europe and North America, while retaining the agility of a boutique…

UK Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France have the talent, capital, and healthcare ecosystems to lead. By linking their world-class clusters, aligning regulation, and pooling investment, they…

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers Gilead’s USD 350mn bet on in vivo CAR-T, GenFleet and Bao Pharma advancing Hong Kong IPOs, Fosun’s USD 670mn global out-licensing deal, new funding rounds for Vibrant and InxMed, and major clinical wins including Akeso’s NSCLC bispecific,…

China Chinese biopharma innovators are making real progress toward global expansion. However, as Vera Zhang of Bristol-Myers Squibb (China) Investment Co., Ltd. writes in DIA’s Global Forum magazine, moving beyond exporting products to building real global brands means investing in strategic international talent acquisition and well-defined roles, all underpinned by a…